These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29486514)

  • 1. Locally acting ACE-083 increases muscle volume in healthy volunteers.
    Glasser CE; Gartner MR; Wilson D; Miller B; Sherman ML; Attie KM
    Muscle Nerve; 2018 Jun; 57(6):921-926. PubMed ID: 29486514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease.
    Pearsall RS; Davies MV; Cannell M; Li J; Widrick J; Mulivor AW; Wallner S; Troy ME; Spaits M; Liharska K; Sako D; Castonguay R; Keates S; Grinberg AV; Suragani RNVS; Kumar R
    Sci Rep; 2019 Aug; 9(1):11392. PubMed ID: 31388039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys.
    St Andre M; Johnson M; Bansal PN; Wellen J; Robertson A; Opsahl A; Burch PM; Bialek P; Morris C; Owens J
    Skelet Muscle; 2017 Nov; 7(1):25. PubMed ID: 29121992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.
    Attie KM; Borgstein NG; Yang Y; Condon CH; Wilson DM; Pearsall AE; Kumar R; Willins DA; Seehra JS; Sherman ML
    Muscle Nerve; 2013 Mar; 47(3):416-23. PubMed ID: 23169607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.
    Statland JM; Campbell C; Desai U; Karam C; Díaz-Manera J; Guptill JT; Korngut L; Genge A; Tawil RN; Elman L; Joyce NC; Wagner KR; Manousakis G; Amato AA; Butterfield RJ; Shieh PB; Wicklund M; Gamez J; Bodkin C; Pestronk A; Weihl CC; Vilchez-Padilla JJ; Johnson NE; Mathews KD; Miller B; Leneus A; Fowler M; van de Rijn M; Attie KM
    Muscle Nerve; 2022 Jul; 66(1):50-62. PubMed ID: 35428982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy.
    Lochmüller H; Behin A; Caraco Y; Lau H; Mirabella M; Tournev I; Tarnopolsky M; Pogoryelova O; Woods C; Lai A; Shah J; Koutsoukos T; Skrinar A; Mansbach H; Kakkis E; Mozaffar T
    Neurology; 2019 Apr; 92(18):e2109-e2117. PubMed ID: 31036580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.
    Campbell C; McMillan HJ; Mah JK; Tarnopolsky M; Selby K; McClure T; Wilson DM; Sherman ML; Escolar D; Attie KM
    Muscle Nerve; 2017 Apr; 55(4):458-464. PubMed ID: 27462804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle strength and hypertrophy occur independently of protein supplementation during short-term resistance training in untrained men.
    Boone CH; Stout JR; Beyer KS; Fukuda DH; Hoffman JR
    Appl Physiol Nutr Metab; 2015 Aug; 40(8):797-802. PubMed ID: 26154345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women.
    Ruckle J; Jacobs M; Kramer W; Pearsall AE; Kumar R; Underwood KW; Seehra J; Yang Y; Condon CH; Sherman ML
    J Bone Miner Res; 2009 Apr; 24(4):744-52. PubMed ID: 19049340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
    Nakatani M; Takehara Y; Sugino H; Matsumoto M; Hashimoto O; Hasegawa Y; Murakami T; Uezumi A; Takeda S; Noji S; Sunada Y; Tsuchida K
    FASEB J; 2008 Feb; 22(2):477-87. PubMed ID: 17893249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creatine Loading Does Not Preserve Muscle Mass or Strength During Leg Immobilization in Healthy, Young Males: A Randomized Controlled Trial.
    Backx EMP; Hangelbroek R; Snijders T; Verscheijden ML; Verdijk LB; de Groot LCPGM; van Loon LJC
    Sports Med; 2017 Aug; 47(8):1661-1671. PubMed ID: 28054322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized Phase 2 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease.
    Thomas FP; Brannagan TH; Butterfield RJ; Desai U; Habib AA; Herrmann DN; Eichinger KJ; Johnson NE; Karam C; Pestronk A; Quinn C; Shy ME; Statland JM; Subramony SH; Walk D; Stevens-Favorite K; Miller B; Leneus A; Fowler M; van de Rijn M; Attie KM
    Neurology; 2022 Jun; 98(23):e2356-e2367. PubMed ID: 35545446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic doses of neostigmine, depolarising neuromuscular blockade and muscle weakness in awake volunteers: a double-blind, placebo-controlled, randomised volunteer study.
    Kent NB; Liang SS; Phillips S; Smith NA; Khandkar C; Eikermann M; Stewart PA
    Anaesthesia; 2018 Sep; 73(9):1079-1089. PubMed ID: 30132821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone.
    Iskenderian A; Liu N; Deng Q; Huang Y; Shen C; Palmieri K; Crooker R; Lundberg D; Kastrapeli N; Pescatore B; Romashko A; Dumas J; Comeau R; Norton A; Pan J; Rong H; Derakhchan K; Ehmann DE
    Skelet Muscle; 2018 Oct; 8(1):34. PubMed ID: 30368252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic administration of follistatin288 increases muscle mass and reduces fat accumulation in mice.
    Gangopadhyay SS
    Sci Rep; 2013; 3():2441. PubMed ID: 23942549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Proteomic and Transcriptomic Analysis of Follistatin-Induced Skeletal Muscle Hypertrophy.
    Barbé C; Bray F; Gueugneau M; Devassine S; Lause P; Tokarski C; Rolando C; Thissen JP
    J Proteome Res; 2017 Oct; 16(10):3477-3490. PubMed ID: 28810121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of myostatin, follistatin and decorin expression in muscle of different origin.
    Hiroki E; Abe S; Iwanuma O; Sakiyama K; Yanagisawa N; Shiozaki K; Ide Y
    Anat Sci Int; 2011 Sep; 86(3):151-9. PubMed ID: 21416223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of myostatin and follistatin in Mdx mice, an animal model for muscular dystrophy.
    Abe S; Soejima M; Iwanuma O; Saka H; Matsunaga S; Sakiyama K; Ide Y
    Zoolog Sci; 2009 May; 26(5):315-20. PubMed ID: 19715499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of vitamin D supplementation alone on muscle function in postmenopausal women: a randomized, double-blind, placebo-controlled clinical trial.
    Cangussu LM; Nahas-Neto J; Orsatti CL; Bueloni-Dias FN; Nahas EA
    Osteoporos Int; 2015 Oct; 26(10):2413-21. PubMed ID: 25956283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting myostatin for therapies against muscle-wasting disorders.
    Tsuchida K
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):487-94. PubMed ID: 18600566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.